Robert A. Figlin, MD | Authors

Articles

Lenvatinib/Everolimus Shows Potential as Second-Line Therapy After CheckMate 9ER Regimen in RCC

May 29, 2021

The CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.

Selecting I-O Agents and Combinations for Patients With RCC

November 27, 2018

Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the considerations behind selecting an immune-oncology agent for the treatment of patients with renal cell carcinoma.

Immunotherapy/TKI Combinations in Advanced RCC

November 08, 2018

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the potential for immunotherapy/TKI combinations in the treatment of advanced renal cell carcinoma.